Helius Medical Technologies

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational Portable Neuromodulation Stimulator (PoNS), that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Helius Medical Technologies reports Q1 revenue, eyes CMS reimbursement boost

Helius Medical Technologies navigated Q1 2024 with a focus on reimbursement, FDA approval, and financial sustainability, supported by financing and market expansion initiatives.
Progress in securing reimbursement, expanding market reach, and addressing demand signals growth potential and market acceptance for the company's products.
Challenges in achieving profitability and executing development plans underscore the importance of timely reimbursement and effective operational strategies.

Helius Medical Technologies navigates revenue challenges with strategic growth initiatives

Helius Medical Technologies faces challenges from program terminations impacting revenue and ongoing operating losses, but maintains a strong cash position with no debt.
Efforts to expand access to PoNS Therapy through strategic partnerships and sales initiatives present growth opportunities in the MS and stroke treatment markets.
The company's financial performance in Q2 2024 reflects a mixed picture of revenue decline, operational losses, and cash stability, with potential for growth pending reimbursement determinations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.

NEWTOWN, Pa., May 31, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that an abstract highlighting real-world data, which shows the impact of translingual neurostimulation as a rehabilitation therapy to improve gait in people with multiple sclerosis (MS), has been selected for a poster presentation at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Meeting taking place June 1-4 in National Harbor, Maryland.

Helius Medical Announces Poster to Be Presented at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Conference

-- Second Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects' adherence to PoNS® therapy for gait improvement in Multiple Sclerosis -- -- Second Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects' adherence to PoNS® therapy for gait improvement in Multiple Sclerosis --

Helius Medical Technologies, Inc. Announces Participation of Dr. Deborah Backus and Shepherd Center in its Therapeutic Experience Program

Helius Medical Technologies, Inc. (NASDAQ:HSDT ) Q1 2022 Earnings Conference Call May 12, 2022 9:00 AM ET Company Participants Judy DiClemente – In-Site Communications, Inc. Dane Andreeff – President and Chief Executive Officer Antonella Favit-Van Pelt – Chief Medical Officer Fred Fantazzia – Vice President-Sales and Marketing, North America Jeff Mathiesen – Chief Financial Officer Conference Call Participants Jeffrey Cohen – Ladenburg Thalmann Operator Welcome to the Helius Medical Technologies Q1 2022 Earnings Conference Call. My name is Richard, and I'll be your operator for today's call.

Helius Medical Technologies' (HSDT) CEO Dane Andreeff on Q1 2022 Results - Earnings Call Transcript

-- Company to host call at 9:00am today with CEO, CFO, CMO and VP Sales & Marketing -- NEWTOWN, Pa., May 12, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended March 31, 2022.

Helius Medical Technologies, Inc. Reports First Quarter 2022 Financial Results and Provides Update on U.S. Commercial Launch of PoNS®

NEWTOWN, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (TSX: HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that the Company will release its first quarter 2022 financial results on Thursday, May 12, 2022, before the markets open.

Helius Medical Technologies, Inc. to Release First Quarter 2022 Financial Results on May 12, 2022

-- First patients have purchased PoNS devices to initiate PoNS Therapy -- -- Nineteen PoNS device prescriptions have been written in the U.S. since recent commercial launch -- NEWTOWN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the fulfillment of the first United States prescriptions of Portable Neuromodulation Stimulator (“PoNS”) therapy for use in multiple sclerosis (“MS”) patients with gait deficit. PoNS has been sold in Canada since 2019.

Helius Medical Technologies, Inc. Fulfills First U.S. Prescriptions for PoNS®

-- Breakthrough technology for MS patients helps patients with gait deficit

Helius Medical Technologies, Inc. Introduces Device in U.S. To Help Multiple Sclerosis Patients Improve Walking Ability

Helius Medical Technologies, Inc. (HSDT) CEO Dane Andreeff on Q4 2021 Results - Earnings Call Transcript

NEWTOWN, Pa., March 14, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter and full year ended December 31, 2021.

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results

NEWTOWN, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT ) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that, effective February 16, 2022, its compensation committee approved equity awards under Helius' 2021 Inducement Plan, as a material inducement to two individuals entering into employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.

Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

-- Fourth Quarter 2021 Revenue Projected to Range from $250,000 to $260,000 -- -- Unaudited Year End Cash Balance of $11 million --

Helius Medical Technologies, Inc. Provides Corporate Update

-- PoNS ® to be used in study of cranial-nerve non-invasive neuromodulation and dynamic gait balance in stroke patients -- -- Collaboration will inform Helius's registrational program in stroke --

Helius Medical Technologies, Inc. Partners with the Medical University of South Carolina in Pilot Trial on Stroke

Patent Readies Company for Next Generation of PoNS Therapy Patent Readies Company for Next Generation of PoNS Therapy

Helius Medical Technologies, Inc. Announces Issuance of U.S. Patent for Wireless PoNS®

Dr. Favit-Van Pelt will present research that led to the FDA authorization of translingual nerve stimulation for gait disturbance in multiple sclerosis Dr. Favit-Van Pelt will present research that led to the FDA authorization of translingual nerve stimulation for gait disturbance in multiple sclerosis

Helius Medical Technologies, Inc.'s Dr. Antonella Favit-Van Pelt to Present at 4th International Brain Stimulation Conference on December 9

NEWTOWN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (Helius), a neurotech company focused on neurological wellness, today announced that Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer, will participate in 1x1 meetings at the 12th Annual Craig-Hallum Alpha Select Conference, being held virtually on Tuesday, November 16, 2021.

Helius Medical Technologies, Inc. to Participate in 1x1 Meetings at 12th Annual Craig-Hallum Alpha Select Conference on November 16, 2021

NEWTOWN, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the closing of its previously announced underwritten public offering of 1,385,031 shares of its Class A common stock at a price to the public of $8.00 per share, for gross proceeds of approximately $11.1 million, including the full exercise of the underwriter's over-allotment option to purchase additional shares of common stock, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company.

Helius Medical Technologies, Inc. Announces Closing of $11.1 Million Underwritten Public Offering of Common Stock Including Full Exercise of Over-Allotment Option

Helius Medical Technologies, Inc. (HSDT) CEO Dane Andreeff on Q3 2021 Results - Earnings Call Transcript

NEWTOWN, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended September 30, 2021.

Helius Medical Technologies, Inc. Reports Third Quarter 2021 Financial Results

Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of -14.86% and 37.98%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Helius Medical Technologies, Inc. (HSDT) Reports Q3 Loss, Tops Revenue Estimates

NEWTOWN, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the pricing of an underwritten registered public offering of 1,204,375 shares of its common stock at a price to the public of $8.00 per share.

Helius Medical Technologies, Inc. Announces Pricing of $9.6 Million Underwritten Public Offering of Common Stock

NEWTOWN, Pa., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that it has commenced a proposed underwritten registered public offering of shares of its common stock.

Helius Medical Technologies, Inc. Announces Proposed Underwritten Public Offering of Common Stock

-- Multi-center, company-sponsored, open label observational interventional trial to evaluate impact of subjects' adherence to PoNS ® therapy for gait improvement in Multiple Sclerosis -- -- Program to include 10-12 U.S. Centers of Excellence; enrollment to commence in Q4 2021 -- NEWTOWN, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the launch of its Therapeutic Experience Program (“TEP”) with NYU Langone Health as its first Center of Excellence. The TEP study is designed to assess adherence to Portable Neuromodulation Stimulator (PoNS) therapy in patients with multiple sclerosis (“MS”).

Helius Medical Technologies, Inc. Launches Therapeutic Experience Program; NYU Langone Health Is Initial Clinical Trial Site

NEWTOWN, Pa., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (Helius or the Company), a neurotech company focused on neurological wellness, today announced it received market authorization from the Australian Therapeutic Goods Administration (TGA) for the sale of PoNS as a Class IIa medical device. The Company's representative in Australia is working with the TGA to finalize the exact scope of the authorization, which is expected to cover the use of PoNS to improve balance and gait when used as an adjunct to a therapeutic exercise program.

Helius Medical Technologies, Inc. Receives PoNS® Market Authorization in Australia

Helius Medical Technologies, Inc. (HSDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Helius Medical Technologies, Inc. (HSDT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

NEWTOWN, Pa., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that the Company will release its third quarter 2021 financial results on Wednesday, November 10, 2021, after the market closes.

News for Helius Medical Technologies Stock (HSDT)